MucoVax

MucoVax is a biotechnology company specializing in the development of mucosal vaccine solutions aimed at addressing infectious diseases, particularly focusing on a genital herpes vaccine candidate. MucoVax was founded in 1998 in Leiden, Netherlands, and is dedicated to developing innovative vaccines. The company raised EUR 3. 1 million in funding from Inventages Venture Capital on November 26, 2003.

The total amount raised to date amounts to EUR 3. 1 million through a single deal, reflecting the company's commitment to advancing its healthcare solutions. Mucosal Vaccine Technologies (MVT) focuses on developing innovative vaccine solutions, with its primary product being a genital herpes (HSV-2) vaccine candidate. This vaccine utilizes MVT's proprietary mucosal vaccine technology to significantly reduce the prevalence of HSV-2, which affects approximately 12% of the U.

S. population aged 14 to 49 and nearly 500 million individuals worldwide. The company's clients include healthcare providers and public health organizations, essential in addressing HSV-2's health implications, particularly its link to increasing susceptibility to HIV. MVT's products target markets not only in the United States but also in regions with high HSV-2 prevalence, as identified by global health studies.

MVT's revenue model is based on the development and eventual commercialization of its HSV-2 vaccine candidate, with funding sourced from the National Institute of Allergy and Infectious Diseases (NIAID) and private investors. Revenue is anticipated to come from partnerships and collaborations with biopharmaceutical firms, healthcare institutions, and potentially government health agencies once the vaccine reaches the market. Transactions may involve direct sales to healthcare providers or through B2B agreements with distributors specializing in immunization products. Specific pricing plans for the vaccine are not disclosed, but the company is positioned to address the substantial market need surrounding HSV-2.

MucoVax plans to leverage its recent funding of EUR 3. 1 million raised in November 2003 to support the ongoing development of its HSV-2 vaccine candidate and explore new market opportunities. The company aims to expand the reach of its vaccine solutions into regions with high HSV-2 prevalence, enhancing global public health initiatives. Additional details on upcoming product launches and timelines will be provided as the development progresses.